EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Recurrent Malignant Glioma - Pipeline Review, H2 2016

  • ID: 4030230
  • Report
  • December 2016
  • 45 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • AbbVie Inc
  • DNAtrix Inc
  • GtreeBNT Co Ltd
  • MORE
Recurrent Malignant Glioma - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2016, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • AbbVie Inc
  • DNAtrix Inc
  • GtreeBNT Co Ltd
  • MORE
Introduction

Recurrent Malignant Glioma Overview

Therapeutics Development

Pipeline Products for Recurrent Malignant Glioma - Overview

Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis

Recurrent Malignant Glioma - Therapeutics under Development by Companies

Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes

Recurrent Malignant Glioma - Pipeline Products Glance

Clinical Stage Products

Recurrent Malignant Glioma - Products under Development by Companies

Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes

Recurrent Malignant Glioma - Companies Involved in Therapeutics Development

2-BBB Medicines BV

AbbVie Inc

DNAtrix Inc

GtreeBNT Co Ltd

Recurrent Malignant Glioma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

2B3-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Recurrent Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target IL-13 for Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

depatuxizumab mafodotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

disufenton sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNX-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recurrent Malignant Glioma - Dormant Projects

Recurrent Malignant Glioma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Recurrent Malignant Glioma, H2 2016

Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Recurrent Malignant Glioma - Pipeline by 2-BBB Medicines BV, H2 2016

Recurrent Malignant Glioma - Pipeline by AbbVie Inc, H2 2016

Recurrent Malignant Glioma - Pipeline by DNAtrix Inc, H2 2016

Recurrent Malignant Glioma - Pipeline by GtreeBNT Co Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Recurrent Malignant Glioma - Dormant Projects, H2 2016

Recurrent Malignant Glioma - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Recurrent Malignant Glioma, H2 2016

Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4
  • 2-BBB Medicines BV
  • AbbVie Inc
  • DNAtrix Inc
  • GtreeBNT Co Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll